Mirum CFO exercises options, sells 5,000 shares

Mirum Pharmaceuticals, Inc. Chief Financial Officer Eric Bjerkholt exercised stock options and sold shares in the company.

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. Chief Financial Officer Eric Bjerkholt exercised stock options and sold shares in the company. On June 9, 2026, he exercised 2,393 Employee Stock Options at an exercise price of $26.49 per share, receiving the same number of common shares. On June 8, 2026, he sold a total of 5,000 common shares in open-market transactions at weighted average prices of $92.84, $93.95 and $95.12, within the disclosed trading ranges. The filing states these transactions were made pursuant to a pre-arranged Rule 10b5-1 Plan. Following these transactions, Bjerkholt directly owns 47,181 common shares of Mirum Pharmaceuticals.

Insights

Equity analyst

CFO exercised options and sold 5,000 shares under a pre-arranged 10b5-1 plan.

Mirum Pharmaceuticals’ CFO, Eric Bjerkholt, exercised 2,393 stock options at an exercise price of $26.49 per share, converting them into common stock. This reflects use of previously granted equity compensation rather than an open-market purchase.

He then executed open-market sales totaling 5,000 shares at weighted average prices of $92.84, $93.95 and $95.12. The filing notes these sales occurred pursuant to a pre-arranged Rule 10b5-1 Plan, indicating they were scheduled in advance.

After the transactions, Bjerkholt holds 47,181 common shares. The net effect is a modest reduction in his share position while still retaining a meaningful stake. The filing does not provide additional financial or strategic information beyond these transactions.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider BJERKHOLT ERIC

Role CHIEF FINANCIAL OFFICER

Sold 5,000 shs ($469K)

Approx. gross sale proceeds $469K

Approx. exercise cost $63K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	2,393	$0.00	$0.00
Exercise	Common Stock	2,393	$26.49	$63K
Sale	Common Stock	2,258	$92.84	$210K
Sale	Common Stock	1,175	$93.95	$110K
Sale	Common Stock	1,567	$95.12	$149K

Holdings After Transaction: Employee Stock Option (right to buy) — 26,653 contracts (Direct); Common Stock — 47,181 shares (Direct)

Footnotes (5)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.
2. F2. . The weighted average sale price for the transaction reported was $92.84, and the range of prices were between $92.485 and $93.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. F3. . The weighted average sale price for the transaction reported was $93.95, and the range of prices were between $93.49 and $94.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
4. F4. . The weighted average sale price for the transaction reported was $95.12, and the range of prices were between $94.62 and $95.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
5. F5. 1/4th of the shares vested one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

Key Figures

Shares sold: 5,000 shares Option shares exercised: 2,393 shares Option exercise price: $26.49/share +4 more

7 metrics

Shares sold 5,000 shares Total common shares sold on June 8, 2026

Option shares exercised 2,393 shares Employee Stock Options exercised on June 9, 2026

Option exercise price $26.49/share Exercise price for Employee Stock Options

Sale price 1 $92.84/share Weighted average sale price for one sale batch

Sale price 2 $93.95/share Weighted average sale price for second sale batch

Sale price 3 $95.12/share Weighted average sale price for third sale batch

Shares owned after 47,181 shares Common shares directly owned post-transactions

Key Terms

Rule 10b5-1 Plan, weighted average sale price, Employee Stock Option (right to buy), vesting, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $92.84"

Employee Stock Option (right to buy) financial

"security_title": "Employee Stock Option (right to buy)""

vesting financial

"1/4th of the shares vested one year after January 23, 2024"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mirum Pharmaceuticals (MIRM) CFO Eric Bjerkholt do in this Form 4?

Mirum’s CFO Eric Bjerkholt exercised 2,393 stock options at $26.49 per share and sold 5,000 common shares in open-market trades. These moves adjusted his equity compensation and liquidity while keeping a substantial remaining share position in the company.

How many Mirum Pharmaceuticals (MIRM) shares did the CFO sell and at what prices?

The CFO sold 5,000 Mirum common shares across three open-market transactions. Weighted average sale prices were $92.84, $93.95, and $95.12 per share, each within disclosed intraday trading ranges detailed in the filing’s footnotes for investor clarity.

How many Mirum Pharmaceuticals (MIRM) shares does the CFO own after these transactions?

After exercising options and selling shares, the CFO directly owns 47,181 Mirum common shares. This post-transaction holding reflects his remaining equity stake in the company following the recent option exercise and 5,000-share open-market sales reported in the Form 4.

Were Mirum Pharmaceuticals (MIRM) CFO’s share sales under a Rule 10b5-1 plan?

Yes. The filing states the reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary market-timing decisions by company insiders like the CFO.

What stock options did the Mirum Pharmaceuticals (MIRM) CFO exercise?

The CFO exercised 2,393 Employee Stock Options with an exercise price of $26.49 per share, receiving 2,393 Mirum common shares. A footnote explains the grant’s vesting schedule, with an initial one-year cliff followed by 36 monthly vesting installments from the first anniversary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 09:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BJERKHOLT ERIC

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/08/2026		S(1)		2,258	D	$92.84(2)	47,530	D
Common Stock	06/08/2026		S(1)		1,175	D	$93.95(3)	46,355	D
Common Stock	06/08/2026		S(1)		1,567	D	$95.12(4)	44,788	D
Common Stock	06/09/2026		M		2,393	A	$26.49	47,181	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$26.49	06/09/2026		M			2,393	(5)	01/22/2034	Common Stock	2,393	$0	26,653	D

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.

2. . The weighted average sale price for the transaction reported was $92.84, and the range of prices were between $92.485 and $93.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. . The weighted average sale price for the transaction reported was $93.95, and the range of prices were between $93.49 and $94.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. . The weighted average sale price for the transaction reported was $95.12, and the range of prices were between $94.62 and $95.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

5. 1/4th of the shares vested one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

	/s/ Judit Ryvkin, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)